Assessing brain aneurysms

ABSTRACT

This document provides methods and materials related to assessing brain conditions within mammals. For example, methods and materials that can be used to determine whether or not a mammal (e.g., a human) with a brain aneurysm is likely to experience brain aneurysm rupture are provided.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No.11/912,540, having a filing date of May 27, 2008; which is a NationalStage application under 35 U.S.C. §371 and claims benefit under 35U.S.C. §119(a) of International Application No. PCT/US2005/014868 havingan International Filing Date of Apr. 29, 2005. The disclosures of theprior applications are considered part of (and are incorporated byreference in) the disclosure of this application.

BACKGROUND

1. Technical Field

This document relates to methods and materials involved in assessingbrain conditions. For example, this document relates to methods andmaterials involved in determining whether or not a brain aneurysm willrupture.

2. Background Information

About 10 to 15 million Americans are thought to suffer from a brainaneurysm with about 30,000 of these experiencing a brain aneurysmrupture (subarachnoid hemorrhage; SAH) annually. Unfortunately, abouthalf of the SAH cases result in death or marked disability from theoriginal hemorrhage or a major complication such as rebleeding orvasospasm. When confronting a patient with a brain aneurysm, a clinicianrecommends either treatment or continued monitoring. Treatment typicallyinvolves surgical clipping, endovascular coiling, or a variationthereof.

SUMMARY

This document involves methods and materials related to assessing brainconditions within mammals. For example, this document provides methodsand materials that can be used to determine whether or not a mammal(e.g., a human) with a brain aneurysm is likely to experience rupture ofthe brain aneurysm. The discrepancy between the prevalence of brainaneurysms (as high as 5 percent or 10 to 15 million in the United Statespopulation alone) and the incidence of aneurysmal rupture (about 30,000cases annually in the United States) suggests that some brain aneurysmsare more prone to rupture than others (Schievink, N. Engl. J. Med.,336:28-40 (1997) and Inagawa et al., Surg. Neurol., 34:361-365 (1990)).Despite diagnostic and therapeutic advances, it is currently estimatedthat one-half of those afflicted with aneurysmal rupture will die or bemarkedly disabled from the original hemorrhage or a major complicationsuch as rebleeding or vasospasm.

Typically, a mammal with a brain aneurysm can be assessed by determiningwhether or not the mammal contains a polymorphism in an eNOS gene. eNOS(endothelial nitric oxide synthase) polypeptides can be constitutivelyexpressed and can catalyze the conversion of L-arginine intoL-citrulline, thereby producing a rapidly diffusing signaling molecule,NO, as the major byproduct. The presence of a polymorphism in an eNOSgene can indicate that the mammal has high likelihood of experiencingbrain aneurysm rupture. Determining whether or not a mammal has a highlikelihood of experiencing brain aneurysm rupture by assessing themammal's eNOS genotype as described herein can help clinicians determinethe best course of treatment for that mammal. For example, a human brainaneurysm patient who normally might not receive surgical or endovasculartreatment may be advised to undergo surgery or endovascular treatment ifit is determined that that patient has an allele having at least onepolymorphism in an eNOS gene.

In general, this document features a method for assessing a human havinga brain aneurysm. The method includes determining whether or not thehuman contains two or more polymorphisms in SEQ ID NO:1, wherein thepresence of the two or more polymorphisms indicates that the brainaneurysm is prone to rupture. The brain aneurysm can be between 2 and 10mm in diameter. The brain aneurysm can be present in an anterior orposterior communicating artery of the human. The human can beheterozygous for the two or more polymorphisms. The human can behomozygous for the two or more polymorphisms. The method can includedetermining whether or not the human contains three or morepolymorphisms in SEQ ID NO:1. The polymorphisms can be selected from thegroup consisting of 27 VNTR, T-786C SNP, and G894T SNP.

In another embodiment, this document features a method for determiningwhether or not to treat a brain aneurysm in a human. The method includesdetermining whether or not the human contains two or more polymorphismsin SEQ ID NO:1, wherein the presence of the two or more polymorphismsindicates that the brain aneurysm should be treated. The brain aneurysmcan be between 2 and 10 mm in diameter. The brain aneurysm can bepresent in an anterior or posterior communicating artery of the human.The human can be heterozygous for the two or more polymorphisms. Thehuman can be homozygous for the two or more polymorphisms. The methodcan include determining whether or not the human contains three or morepolymorphisms in SEQ ID NO:1. The polymorphisms can be selected from thegroup consisting of 27 VNTR, T-786C SNP, and G894T SNP. The method caninclude determining the size of the brain aneurysm. The method caninclude determining the location of the brain aneurysm.

In another embodiment, this document features a method for determiningwhether or not to treat a brain aneurysm in a human. The method includes(a) determining whether or not the human contains two or morepolymorphisms in SEQ ID NO:1, and (b) determining whether or not thebrain aneurysm has a size between 2 and 10 mm in diameter or determiningwhether or not the brain aneurysm has a location in an anterior orposterior communicating artery of the human, wherein the presence of thetwo or more polymorphisms in the human and the presence of the size orthe location indicates that the brain aneurysm should be treated. Themethod can include determining whether or not the human is homozygousfor the two or more polymorphisms. The human can be heterozygous for thetwo or more polymorphisms. The human can be homozygous for the two ormore polymorphisms. The method can include determining whether or notthe human contains three or more polymorphisms in SEQ ID NO:1. Thepolymorphisms can be selected from the group consisting of 27 VNTR,T-786C SNP, and G894T SNP. The method can include determining whether ornot the brain aneurysm has a size between 2 and 10 mm in diameter anddetermining whether or not the brain aneurysm has a location in ananterior or posterior communicating artery of the human, wherein thepresence of the two or more polymorphisms in the human and the presenceof the size and the location indicates that the brain aneurysm should betreated.

Unless otherwise defined, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this invention pertains. Although methods and materialssimilar or equivalent to those described herein can be used in thepractice or testing of the present invention, suitable methods andmaterials are described below. All publications, patent applications,patents, and other references mentioned herein are incorporated byreference in their entirety. In case of conflict, the presentspecification, including definitions, will control. In addition, thematerials, methods, and examples are illustrative only and not intendedto be limiting. Other features and advantages of the invention will beapparent from the following detailed description, and from the claims.

DESCRIPTION OF DRAWINGS

FIG. 1 is a diagram depicting three eNOS gene polymorphisms along withtheir respective locations in the eNOS gene. For each polymorphism, theputative abnormal allele is indicated by an asterisk. Abbreviations:4a=four 27-base pair tandem repeats; 4b=five 27-base pair tandemrepeats; C=cytosine; G=guanine; kbp=kilobase-pairs; NO=nitric oxide;SNP=single nucleotide polymorphism; T=thymine; TIS=transcriptioninitiation sequence; VNTR=variable number tandem repeat.

FIG. 2 is a nucleic acid sequence listing of a human eNOS gene (SEQ IDNO:1).

FIG. 3 is an amino acid sequence listing of a human eNOS polypeptide(SEQ ID NO:2).

FIG. 4 is a listing of the human eNOS gene set forth in FIG. 1 labelingexons, untranslated regions (UTR), and polymorphisms. The nucleic acidsequence is as set forth in SEQ ID NO:1, while the amino acid sequenceis as set forth in SEQ ID NO:2.

DETAILED DESCRIPTION

This document provides methods and materials related to assessing brainconditions within mammals. For example, this document provides methodsand materials that can be used to determine whether or not a mammal(e.g., a human) with a brain aneurysm is likely to experience brainaneurysm rupture. As described herein, a mammal having a polymorphism inan eNOS gene can have a higher likelihood of experiencing brain aneurysmrupture than a mammal not having a polymorphism in an eNOS gene. Theterm “eNOS gene” as used herein includes the exons that encode an eNOSpolypeptide, any introns located between such exons, the promoterregion, the sequences up to 3 kilobases (e.g., 0.5, 1, 1.5, 2, 2.5, or 3kilobases) 5′ of the transcriptional start site, and the sequences up to3 kilobases (e.g., 0.5, 1, 1.5, 2, 2.5, or 3 kilobases) 3′ of the stopcodon. For example, the sequence set forth in SEQ ID NO:1 (FIG. 2) canbe an eNOS gene in the case of a human. See, also, GenBank® AccessionNo. AF519768.

Any mammal having a brain aneurysm can be assessed to determine whetheror not the mammal has a high likelihood of experiencing brain aneurysmrupture. For example, dogs, cats, horses, pigs, cows, sheep, monkeys,and humans can be assessed for the presence or absence of a polymorphismin an eNOS gene. The nucleic acid sequence for a particular mammalianspecies can be found in GenBank® or can be determined using commonmolecular biology techniques. In some cases, several eNOS genes can besequenced from multiple members of the same species to determine acommon wild-type sequence to which polymorphic sequences can becompared. In the case of humans, the sequence set forth in SEQ ID NO:1can be used as a wild-type sequence to which polymorphic sequences arecompared. For example, any sequence deviation from the sequence setforth in SEQ ID NO:1 found in a human can be considered a polymorphism.In some cases, the first or consensus nucleic acid sequence deposited inGenBank® for a particular mammalian species can be used as a wild-typesequence to which polymorphic sequences are compared for that species.

A mammal can be assessed to determine whether or not that mammalcontains any type of polymorphism in an eNOS gene including, withoutlimitation, insertions, deletions, substitutions, repeats, invertedrepeats, and combinations thereof. In some embodiments, a human can beassessed to determine whether or not the human contains the intron-427-base pair variable-number-tandem-repeat polymorphism, 27 VNTR; thepromoter SNP, T-786C SNP; or the exon-7 SNP, G894T SNP (FIG. 1).Additional examples of polymorphisms that can be used in the case ofhumans include, without limitation, any of the polymorphisms provided inFIG. 3 or set forth in the Single Nucleotide Polymorphism database ofGenBank® with any of the following reference SNP identification numbers:rs3918234; rs1799983; rs3918166; rs3918232; rs3918201; rs3918155;rs1800779; rs3918158; rs3918157; rs2243310; rs3918163; rs2070744;rs3918225; rs10952298; rs3918226; rs3918159; rs3918160; rs2243311;rs3918162; rs3918156; rs3918161; rs1800783; rs2853792; rs3918170;rs3918192; rs1008140; rs1800782; rs3918187; rs7830; rs2853795;rs3918205; rs3730002; rs3918202; rs3918178; rs753482; rs3918193;rs3918204; rs3918237; rs3918164; rs1800781; rs1800780; rs3918177;rs3918231; rs3918194; rs3730305; rs743507; rs3918184; rs3730009;rs867225; rs3918228; rs3918182; rs3918195; rs3918207; rs1007311;rs3918235; rs3918230; rs3918185; rs3918169; rs3730001; rs2853796;rs3834873; rs3918227; rs3918175; rs3918165; rs3793341; rs3918209;rs3918176; rs3918196; rs1541861; rs3730003; rs3918188; rs3793342;rs2566511; rs3918208; rs3918174; rs3918167; rs2256314; rs3918197;rs1065300; rs3918229; rs3918203; rs1808593; rs3918198; rs3918180;rs891511; rs3918236; rs891512; rs3918189; rs3729625; rs3918210;rs3918173; rs3918168; rs743506; rs3918181; rs3918190; rs3918199;rs3918200; rs3918191; rs3918186; rs7792133; rs6947833; rs2566516;rs2566519; rs11371169; rs3730306; rs2566508; rs3730007; rs13305985;rs3918179; rs2853791; rs13420; rs1799984; rs13310854; rs10539416;rs2566506; rs2566517; rs6969597; rs12937; rs2853797; rs2853794;rs2566510; rs10539415; rs13311313; rs13310763; rs2566507; rs10595051;rs2853793; rs3730012; rs2566513; rs11974098; rs3918183; rs13305984;rs2566512; rs13311166; rs13310774; rs3730006; rs1799985; rs7776461;rs2853798; rs2566518; rs13305982; rs3730010; rs2853800; rs2566515;rs2566509; rs10255980; rs4725985; rs3828997; rs933163; rs3134740;rs11771443; or rs10531586.

A mammal can be assessed to determine whether or not that mammalcontains a single polymorphism or multiple polymorphisms in an eNOSgene. For example, a mammal can be assessed to determine whether or notthat mammal contains one, two, three, four, five, six, seven, eight,nine, ten, or more polymorphisms in an eNOS gene. In some embodiments, ahuman can be assessed to determine whether or not the human contains anycombination of the polymorphisms provided herein such as (1) 27 VNTR,T-786C SNP, and G894T SNP; (2) 27 VNTR and T-786C SNP; (3) 27 VNTR andG894T SNP; (4) T-786C SNP and G894T SNP; (5) 27 VNTR and any of thepolymorphisms provided in FIG. 3; (6) T-786C SNP and any of thepolymorphisms provided in FIG. 3; or (7) G894T SNP and any of thepolymorphisms provided in FIG. 3. The polymorphisms in an eNOS gene canbe present on the same allele or on different alleles. For example, ahuman having two polymorphisms in an eNOS gene such as the 27 VNTR andT-786C SNP can have one allele containing both the 27 VNTR and T-786CSNP, or can have one allele containing the 27 VNTR and the other allelecontaining the T-786C SNP. In addition, a mammal can be heterozygous orhomozygous for a particular polymorphism. For example, one allele cancontain the T-786C SNP, or both alleles can contain the T-786C SNP.

Since a mammal having one or more polymorphisms (e.g., one, two, three,four, five, six, seven eight, nine, ten, or more polymorphisms) in aneNOS gene can have a higher likelihood of experiencing brain aneurysmrupture than a mammal not having those polymorphisms in an eNOS gene,the methods and materials provided herein can be used to determinewhether or not to treat a brain aneurysm in a mammal. In some cases, thesize of a brain aneurysm, the location of a brain aneurysm, or both canbe used in addition to assessing the mammal for the presence or absenceof polymorphisms in an eNOS gene to determine whether or not to treatthe brain aneurysm. Typically, a clinician can recommend treating abrain aneurysm surgically when any one, two, or three of the followingare determined: (1) the brain aneurysm's size is between 1 and 35 mm(e.g., between 1 and 20 mm, between 1 and 15 mm, between 2 and 10 mm,between 2 and 8 mm, or between 3 and 6 mm) in diameter, (2) the brainaneurysm's location is in the human's intracranial circulation (e.g., inan anterior or posterior communicating artery), and (3) the mammalcontains one or more polymorphisms in an eNOS gene.

Any common diagnostic technique can be used to identify a mammal havinga brain aneurysm. For example, diagnostic techniques such as cerebralangiography, magnetic resonance angiography (MRA), or computerizedtomographic angiography (CTA) can be used to identify the presence,size, and location of a brain aneurysm within a mammal (e.g., a human).In addition, any method can be used to determine whether or not a mammalcontains a polymorphism in an eNOS gene. For example, polymorphisms inan eNOS gene can be detected by sequencing or by performingallele-specific hybridization, allele-specific restriction digests,mutation specific polymerase chain reactions (MSPCR), single-strandedconformational polymorphism (SSCP) detection (Schafer et al., Nat.Biotechnol., 15:33-39 (1995)), denaturing high performance liquidchromatography (DHPLC, Underhill et al., Genome Res., 7:996-1005(1997)), infrared matrix-assisted laser desorption/ionization (IR-MALDI)mass spectrometry (WO 99/57318), or combinations of such methods.

Genomic DNA or mRNA can be used in the analysis of polymorphisms.Genomic DNA is typically extracted from a biological sample such asblood, but can be extracted from other biological samples includingtissue samples. Routine methods can be used to extract genomic DNA froma blood or tissue sample, including, for example, phenol extraction.Alternatively, genomic DNA can be extracted with kits such as theQIAamp® Tissue Kit (Qiagen, Chatsworth, Calif.), Wizard® Genomic DNApurification kit (Promega), and the A.S.A.P.™ Genomic DNA isolation kit(Boehringer Mannheim, Indianapolis, Ind.). In some cases, anamplification step can be performed prior to detecting a polymorphism.For example, nucleic acid from an eNOS gene can be amplified and thendirectly sequenced. Dye primer sequencing can be used to increase theaccuracy of detecting heterozygous samples.

Hybridization also can be used to detect polymorphisms. See, forexample, Stoneking et al., Am. J. Hum. Genet., 48:370-382 (1991) andPrince et al., Genome Res., 11:152-162 (2001). In practice, samples ofDNA or RNA from one or more individuals can be amplified using pairs ofprimers, and the resulting amplification products can be immobilized ona substrate (e.g., in discrete regions). Hybridization conditions can beselected such that an oligonucleotide binds to a sequence of interest,e.g., a polymorphic nucleic acid sequence. Such hybridizations typicallyare performed under high stringency as some polymorphic nucleic acidsequences include only a single nucleotide difference. High stringencyconditions can include the use of low ionic strength solutions and hightemperatures for washing. For example, nucleic acid molecules can behybridized at 42° C. in 2×SSC (0.3M NaCl/0.03 M sodium citrate) with0.1% sodium dodecyl sulfate (SDS) and washed in 0.1×SSC (0.015MNaCl/0.0015 M sodium citrate), 0.1% SDS at 65° C. Hybridizationconditions can be adjusted to account for unique features of the nucleicacid molecule, including length and sequence composition. Probes can belabeled (e.g., fluorescently or with biotinylation) to facilitatedetection.

For polymorphic nucleic acid sequences that introduce a restrictionsite, restriction digest(s) with the appropriate restriction enzyme(s)can differentiate wild-type and polymorphic sequences. For polymorphicsequences that do not alter a common restriction site, mutagenic primerscan be designed that introduce a restriction site when the polymorphicsequence is present or when a wild-type sequence is present. A portionof an eNOS gene can be amplified using the mutagenic primer and awild-type primer, followed by digest with the appropriate restrictionendonuclease.

Certain polymorphic sequences, such as insertions or deletions of one ormore nucleotides, can change the size of a DNA fragment encompassing apolymorphism. The insertion or deletion of nucleotides can be assessedby amplifying the region encompassing the polymorphic sequence anddetermining the size of the amplified products in comparison with sizestandards. For example, a region of an eNOS gene that encodes an eNOSpolypeptide or regulates expression of an eNOS polypeptide can beamplified using a primer set from either side of a polymorphic sequence.One of the primers is typically labeled, for example, with a fluorescentmoiety, to facilitate sizing. The amplified products can beelectrophoresed through acrylamide gels with a set of size standardsthat are labeled with a fluorescent moiety that differs from the primer.

In some embodiments, PCR conditions and primers can be developed thatamplify a product only when a particular polymorphic sequence is presentor only when the polymorphic sequence is not present (MSPCR orallele-specific PCR). For example, patient DNA and a control can beamplified separately using either a wild-type primer or a primerspecific for a polymorphic sequence. Each set of reactions can then beexamined for the presence of amplification products using standardmethods to visualize the DNA. For example, the reactions can beelectrophoresed through an agarose gel, and the DNA visualized bystaining with ethidium bromide or other DNA intercalating dye. Innucleic acid samples from heterozygous mammals, reaction products can bedetected with each set of primers. Mammalian samples containing solelythe wild-type allele would have amplification products only in thereaction using the wild-type primer. Similarly, mammalian samplescontaining solely the polymorphic allele can have amplification productsonly in the reaction using the primer containing the polymorphicsequence. Allele-specific PCR also can be performed usingallele-specific primers that introduce priming sites for two universalenergy-transfer-labeled primers (e.g., one primer labeled with a greendye such as fluoroscein and one primer labeled with a red dye such assulforhodamine).

Amplification products can be analyzed for green and red fluorescence ina plate reader. See, Myakishev et al., Genome, 11(1):163-169 (2001).

Mismatch cleavage methods also can be used to detect differing sequencesby PCR amplification, followed by hybridization with a wild-typesequence and cleavage at points of mismatch. Chemical reagents, such ascarbodiimide or hydroxylamine and osmium tetroxide can be used to modifymismatched nucleotides to facilitate cleavage.

The invention will be further described in the following examples, whichdo not limit the scope of the invention described in the claims.

EXAMPLES Example 1 The Presence of Tandem eNOS Gene PolymorphismsIdentifies Brain Aneurysms Prone to Rupture

The following experiments were performed to determine whetherpolymorphisms in eNOS can be used to identify brain aneurysms prone torupture.

Study Participants

A prospective case-control study involved 107 human subjects each ofwhom gave informed consent for participation. The control groupconsisted of 49 people consecutively presenting to the Mayo Clinic witha diagnosis of unruptured intracranial saccular aneurysm. The case groupwas comprised of 58 people consecutively admitted to the Mayo Clinicdiagnosed with aneurysmal subarachnoid hemorrhage (SAH) based on historyand radiological findings, including both admission head computerizedtomography scan and 4-vessel cerebral angiography.

Genetic Analysis

Three particular eNOS polymorphisms were analyzed (FIG. 1). A single 20mL sample of peripheral venous blood was obtained from all participantsfor subsequent DNA extraction and genetic analysis. Genomic DNA wasextracted from peripheral blood lymphocytes using QIAamp® DNA BloodMinikit (Qiagen, Germantown, Md.). SNPs were genotyped using Nanochip™active electronic arrays (Nanogen, San Diego, Calif.) as describedelsewhere (Sohni et al., Clin. Chem., 47:1922-1924 (2002)). Oligo 6.61software was used to design polymerase chain reaction (PCR) primers(IDT, Coralville, Iowa) based on GenBank sequences. PCR mixturesconsisted of 25 μL AmpliTaq Gold Master Mix (Applied Biosystems, FosterCity, Calif.), 1 μM primers, 20 ng DNA template and water to 50 μL. Alloligonucleotides were synthesized by IDT. Primer sequences were5′-biotin-GCATGCACTCTGGCCTGAAGT-3′ (forward; SEQ ID NO:3) and5′-CAGGAAGCTGCCTTCCAGTGC-3′ (reverse; SEQ ID NO:4) for eNOS T-786C SNP,and 5′-biotin-CTGGAGATGAAGGCAGGAGAC-3′ (forward; SEQ ID NO:5) and5′-CTCCATCCCACCCAGTCAATC (reverse; SEQ ID NO:6) for eNOS G894T SNP.Thermal cycling conditions for each were 95° C. for 10 minutes, 30cycles of 94° C. for 30 seconds, 58° C. for 30 seconds, and 72° C. for45 seconds, and final extension at 72° C. for 7 minutes. For eNOS T-786CSNP, reporter probes were 5′-Cy3-AGGGTCAGCCA-3′ (SEQ ID NO:7) and5′-Cy5-GGGTCAGCCG-3′ (SEQ ID NO:8) with stabilizer oligonucleotide5′-GCCAGGGAAGAGCTTGATGCCCTGGTGGGAGC-3′ (SEQ ID NO:9). For eNOS G894TSNP, reporter probes were 5′-Cy3-GTTCTGGGGGC-3′ (SEQ ID NO:10) and5′-Cy5-AGTTCTGGGGGA-3′ (SEQ ID NO:11) with stabilizer oligonucleotide5′-TCATCTGGGGCCTGCAGCAGCAGGGGCAGCA-3′ (SEQ ID NO:12). Knownheterozygotes, verified by dye-terminator sequencing performed on ABI377 DNA sequencers in both forward and reverse directions, were used ascontrols to normalize hybridization efficiency between dye-labeledreporters. PCR conditions and methods for analyzing the eNOS 27 VNTRpolymorphism are detailed elsewhere (Sohni et al., Clin. Biochem.,36:35-39 (2003)). PCR products were analyzed using DNA 500 LabChip® kiton Agilent 2100 Bioanalyzer (Agilent Technologies, Wilmington, Del.)following the manufacturer's instructions. DNA fragment sizes weredetermined for each sample from the calibration curve in conjunctionwith markers and sizing ladder. Genotypes were designated based onfragment sizes obtained at the end of the run. For each polymorphism,amplicons were randomly sequenced to determine concordance withmicroarray genotyping as described herein.

Data Analysis

In order to evaluate the association between the demographic and geneticmarkers of interest and aneurysmal disease, comparisons were madebetween cases and controls. Demographics are presented as mean±standarddeviation (SD) for continuous variables and percentage of column totalsfor categorical variables. Univariate associations between demographicvariables and disease were assessed using two-sample t-test forcontinuous variables and Pearson's chi-square or Fisher's exact test(when sample sizes were limited) for categorical variables. Before anystatistical analysis of disease-marker associations, allele frequencydistribution at each polymorphism locus was tested againstHardy-Weinberg equilibrium (HWE) under Mendelian bi-allelic expectationusing the chi-square test. Univariate associations of allele (whichtreats each chromosome as a unit) and genotype (which treats a person asa unit) with disease were evaluated using contingency table methods inSAS-v8.2. Allele associations were assessed using Pearson's chi-squareor Fisher's exact test (when sample sizes were limited) and genotypeassociations were assessed using the Cochran-Armitage trend test. Themultiple polymorphism marker-disease association with haplotype wasevaluated using Haplo.score which accounts for ambiguous linkage phase(Lake et al., Hum. Hexed., 55:56-65 (2002) and Schaid et al., Am. J.Hum. Genet., 70:425-434 (2002)). Haplotype odds ratios (OR) and 95%confidence intervals (CI) were calculated using Haplo.glm. The haplotypecomprised of 3 wild-type alleles (4b-T-G) was used as the comparison tocalculate the haplotype specific OR and CI. Linkage disequilibrium wasassessed using the Graphical Overview of Linkage Disequilibrium (GOLD)software package (Abecasis and Cookson, Bioinformatics, 16:182-3 (2002)and Ardlie et al., Nat. Rev. Genet., 3:299-309 (2002)). All tests weretwo-sided and P-values <0.05 were considered statistically significant.

Clinical Data

When comparing aneurysm cases and controls, there was no significantdifference in mean age, gender or race, history of cardiovasculardiseases or smoking, or family history of brain aneurysms or SAH (Table1). Although multiplicity of aneurysms was similar between the twogroups, cases presented with significantly smaller aneurysms comparedwith controls (7.5±4.7 mm vs. 9.6±5.8 mm; P=0.037). The distribution andtreatment of aneurysms also differed significantly between the twogroups (P<0.001; Table 1).

TABLE 1 Demographic and clinical data for people with unruptured(controls) compared with ruptured (subarachnoid hemorrhage; SAH; cases)brain aneurysms. Variable Controls (n = 49) Cases (n = 58) P-value Age57.1 ± 11.5 53.2 ± 12.7 0.10 Female gender 36 (73%) 39 (67%) 0.48Caucasian race 49 (100%) 58 (100%) N/A Cardiovascular comorbidities:Diabetes mellitus 4 (8%) 4 (7%) 0.80 Hypertension 25 (51%) 24 (41%) 0.32Coronary artery disease 4 (8%) 7 (12%) 0.51 Ischemic stroke 10 (20%) 5(9%) 0.08 History of smoking 28 (57%) 41 (71%) 0.14 Family history ofbrain 8 (16%) 4 (7%) 0.12 aneurysm or SAH Aneurysm size (mm) 9.6 + 5.87.5 + 4.7 0.037 Multiple aneurysms 16 (33%) 15 (26%) 0.44 Aneurysmlocation: <0.001 Anterior communicating 3 (6%) 16 (28%) artery Anteriorcerebral artery 2 (4%) 5 (9%) Middle cerebral artery 17 (35%) 5 (9%)Internal carotid artery 17 (34%) 7 (12%) Posterior 1 (2%) 13 (22%)communicating artery Posterior cerebral artery 1 (2%) 2 (3%) Basilarartery 6 (12%) 7 (12%) Vertebral artery 2 (4%) 3 (5%) Aneurysmtreatment: <0.001 Clip 22 (45%) 24 (41%) Coil 10 (20%) 30 (52%) Coilthen clip 0 1 (2%) None 17 (35%) 3 (5%)Genetic Data

Hardy-Weinberg Equilibrium (HWE): Among controls, the genotypefrequencies for eNOS 27 VNTR (P=1.0) and eNOS G894T SNP (P=0.06) were inagreement with those predicted by the HWE. The genotype frequencies foreNOS T-786C SNP (P=0.03) were not in agreement with those predicted bythe HWE. Thus, the Cochran-Armitage trend test (which is unaffected bydeparture from HWE) was implemented and revealed consistent results. Forthe eNOS T-786C SNP, the departure from HWE was due to a homozygotefavoring which was shown to have minimal effect on haplotype estimation(Lake et al., Hum. Hered., 55:56-65 (2002)). Further, to exclude thepossibility of genotyping error, thirty-seven T-786C SNP amplicons wererandomly sequenced, and the results were found to be fully concordantwith microarray genotyping.

Allele and Genotype Frequencies: For each of the three polymorphisms,significant differences in allele and genotype frequency were foundbetween cases and controls with the variant alleles and theircorresponding genotypes being present two-to-four times more often amongcases (Table 2). Linkage disequilibrium analysis (Ardlie et al., Nat.Rev. Genet., 3:299-309 (2002)) was carried out using both D′ and R2 todetect pair-wise linkage disequilibrium among the three polymorphisms.No significant linkage disequilibrium was detected.

TABLE 2 Allele and genotype data for people with unruptured (controls)compared with ruptured (cases) brain aneurysms. Controls (n = 49) Cases(n = 58) Locus N (%) N (%) P-value Allele frequency: eNOS 27 VNTR 0.003Allele 4a^(†) 10 (10) 30 (26) Allele 4b 88 (90) 86 (74) eNOS T-786C SNP0.003 Allele C^(†) 21 (21) 47 (41) Allele T 77 (79) 69 (59) eNOS G894TSNP <0.001 Allele T^(†) 10 (10) 38 (33) Allele G 88 (90) 78 (67)Genotype frequency: eNOS 27 VNTR 0.006 4a/4a 0 1 (2) 4a/4b 10 (20) 28(48) 4b/4b 39 (80) 29 (50) eNOS T-786C SNP <0.001 C/C 5 (10) 6 (10) C/T11 (22) 35 (60) T/T 33 (67) 17 (29) eNOS G894T SNP <0.001 T/T 2 (4) 6(10) T/G 6 (12) 26 (45) G/G 41 (84) 26 (45) ^(†)Variant alleleHaplotype Frequencies

A haplotype analysis consisting of 20,000 simulations was implemented toassess the multiple polymorphism marker-disease associations. Theobserved results were summarized using the simulated P-value, controland case haplotype frequencies, OR, and the 95% CI for each of the eightpossible haplotypes (Table 3). Haplotype 4a-C-T, which includes thevariant allele for all 3 polymorphisms, was found in 8.4% of cases and2.3% of controls (simulated P=0.0038), and subjects having thishaplotype had an 11.4-fold (1.7-75.9 95% CI) increased odds of being acase. The second identified risk haplotype 4a-C-G, which includes thevariant allele for eNOS 27 VNTR and eNOS T-786C SNP, was found in 14.1%of cases and 3.1% of controls (simulated P=0.0196), and subjects havingthis haplotype had an 8.6-fold (1.8-41.3 95% CI) increased odds of beinga case. The third risk haplotype 4b-C-T, which includes the variantallele for eNOS T-786C SNP and eNOS G894T SNP, was found in 13.2% ofcases and 2.7% of controls (simulated P=0.0077), and subjects havingthis haplotype had a 9.3-fold (1.7-49.9 95% CI) increased odds of beinga case.

TABLE 3 Haplotype data for people with unruptured (controls) comparedwith ruptured (cases) brain aneurysms. eNOS eNOS eNOS Control Odds ratio27 T-786C G894T Simulated Haplotype Case Haplotype (95% confidence VNTRSNP SNP P-value Frequency Frequency interval) 4a C T 0.004 0.02 0.0811.4 (1.7-75.9) 4a T T NA 0.01 <0.001 NA 4a C G 0.02 0.03 0.14  8.6(1.8-41.3) 4a T G 0.87 0.04 0.03  2.2 (0.4-13.1) 4b C T 0.008 0.03 0.13 9.3 (1.7-49.9) 4b T T 0.07 0.04 0.11  4.4 (0.9-22.4) 4b C G 0.1 0.130.05  0.5 (0.1-1.8) 4b T G <0.001 0.70 0.45  1.0 (NA)

The results provided herein demonstrate that the presence of two or morevariant eNOS alleles in a brain aneurysm patient is associated with anapproximately 10-fold increased odds of presenting with aneurysmalrupture. The results also demonstrate that there are two distinctsubpopulations of intracranial aneurysms, distinguishable by anatomicaland genetic features, with one being more prone to rupture than theother.

The precise molecular effects of eNOS polymorphisms have not beenelucidated, although there is biochemical evidence for decreased eNOSgene promoter activation associated with the T-786C SNP variant andreduced eNOS polypeptide expression and enzymatic activity associatedboth with eNOS 27 VNTR and T-786C polymorphism variants (Nakayama etal., Circulation, 99:2864-2870 (1999) and Song et al., Clin. Chem.,49:847-852 (2003)). It is certainly conceivable that such variants maycontribute towards aneurysm pathobiology and cerebral vasospasm throughincreased local oxidative stress leading to vessel wall damage,predilection towards development of atherogenic intimal hyperplasia andsystemic hypertension, the presence of aberrant vascular smooth muscleproliferation, and increased platelet aggregation and pro-inflammatorymonocyte adhesion, all of which are associated with NO signalingdysfunction. Such mechanisms may also account for the impairedvasorelaxation and heightened vascular wall inflammation characteristicof post-SAH vasospasm.

The results provided herein demonstrate the existence of rupture-proneversus rupture-resistant subpopulations of brain aneurysms. Despite thesimilarities of demographic and clinical characteristics between the twogroups, the genetic differences between the two groups were strikingPolymorphic variant alleles and their corresponding genotypes were foundto be between two-to-four times more frequent among cases compared withcontrols, and the haplotype analysis indicated that the presence of twoor more (e.g., three) variant alleles was associated with an 8.6 to 11.4increased odds of being a case (i.e., presenting with a ruptured brainaneurysm). Taken together, the anatomical and genetic data suggest thatthere are distinct differences between ruptured compared with unrupturedaneurysms: the former are smaller, have a greater predilection for theanterior and posterior communicating arteries, and have a tendency tooccur more commonly in persons with two or more (e.g., three) varianteNOS polymorphic alleles.

Clinical Implication of these Results

Among the estimated 5-15% of aneurysm-harboring individuals with arelatively strong family history of brain aneurysms or with a heritableconnective tissue disorder (such as Ehlers-Danlos, Marfan, or autosomaldominant polycystic kidney disease), noninvasive radiological screeningfor brain aneurysms is accepted as being worthwhile. For the remainingmajority of people at this time referred to as having “sporadic”unruptured brain aneurysms; however, there is currently no adequatescreening tool. To identify such individuals via population-wide serialradiological screening seems largely impractical, and there is no“aneurysm gene” yet identified. An important aspect of brain aneurysmmanagement at this time can be how to counsel a patient with a newlydiagnosed brain aneurysm (e.g., observation versus treatment). ISUIA hassuggested certain aneurysms are more prone to rupture; however, counselbased on ISUIA data alone may not cover the gamut of rupture-proneaneurysms. As described herein, a person diagnosed incidentally orotherwise with an unruptured intracranial aneurysm (especially onelocated in a higher-risk cerebrovascular territory) and in whom two ormore (e.g., three) variant eNOS polymorphic alleles are found, forexample, by gene microarray technology, can be counseled towards earliertreatment rather than observation. In addition, a rapid andcost-effective eNOS polymorphism screening tool can be used byclinicians as a genetic aid to predicting rupture risks in patientspresenting with unruptured intracranial aneurysms.

Other Embodiments

It is to be understood that while the invention has been described inconjunction with the detailed description thereof, the foregoingdescription is intended to illustrate and not limit the scope of theinvention, which is defined by the scope of the appended claims. Otheraspects, advantages, and modifications are within the scope of thefollowing claims.

1. A method for assessing a human having a brain aneurysm, said methodcomprising: (a) detecting the presence of two or more polymorphisms inSEQ ID NO:1 in said human, wherein at least two of said two or morepolymorphisms are selected from the group consisting of 27 VNTR, T-786CSNP, and G894T SNP, and wherein the presence of said two or morepolymorphisms indicates that said brain aneurysm is prone to rupture,and (b) classifying said human as having a brain aneurysm that is proneto rupture.
 2. The method of claim 1, wherein said brain aneurysm isbetween 2 and 10 mm in diameter.
 3. The method of claim 1, wherein saidbrain aneurysm is present in a location selected from the groupconsisting of an anterior communicating artery, an anterior cerebralartery, a middle cerebral artery, an internal carotid artery, aposterior communicating artery, a posterior cerebral artery, a basilarartery, and a vertebral artery.
 4. The method of claim 1, wherein saidhuman is heterozygous for said two or more polymorphisms.
 5. The methodof claim 1, wherein said human is homozygous for said two or morepolymorphisms.
 6. The method of claim 1, wherein said method comprisesdetecting three or more polymorphisms in SEQ ID NO:1 in said human.
 7. Amethod for determining to treat a brain aneurysm in a human, said methodcomprising: (a) detecting the presence of two or more polymorphisms inSEQ ID NO:1 in said human, wherein at least two of said two or morepolymorphisms are selected from the group consisting of 27 VNTR, T-786CSNP, and G894T SNP, and wherein the presence of said two or morepolymorphisms indicates that said brain aneurysm should be treated, and(b) classifying said human as having a brain aneurysm that should betreated.
 8. The method of claim 7, wherein said brain aneurysm isbetween 2 and 10 mm in diameter.
 9. The method of claim 7, wherein saidbrain aneurysm is present in a location selected from the groupconsisting of an anterior communicating artery, an anterior cerebralartery, a middle cerebral artery, an internal carotid artery, aposterior communicating artery, a posterior cerebral artery, a basilarartery, and a vertebral artery.
 10. The method of claim 7, wherein saidhuman is heterozygous for said two or more polymorphisms.
 11. The methodof claim 7, wherein said human is homozygous for said two or morepolymorphisms.
 12. The method of claim 7, wherein method comprisesdetecting three or more polymorphisms in SEQ ID NO:1 in said human. 13.The method of claim 7, wherein said method comprises determining thesize of said brain aneurysm.
 14. The method of claim 7, wherein saidmethod comprises determining the location of said brain aneurysm.
 15. Amethod for determining to treat a brain aneurysm in a human, said methodcomprising: (a) detecting the presence of two or more polymorphisms inSEQ ID NO:1 in said human, wherein at least two of said two or morepolymorphisms are selected from the group consisting of 27 VNTR, T-786CSNP, and G894T SNP, (b) determining that the size of said brain aneurysmis between 2 and 10 mm in diameter or determining that the location ofsaid brain aneurysm is in an anterior communicating artery or aposterior communicating artery of said human, wherein the presence ofsaid two or more polymorphisms in said human and the presence of saidsize or said location indicates that said brain aneurysm should betreated, and (c) classifying said human as having a brain aneurysm thatshould be treated if said brain aneurysm comprises said size or saidlocation.
 16. The method of claim 15, wherein said method comprisesdetermining that said human is homozygous for said two or morepolymorphisms.
 17. The method of claim 15, wherein said human isheterozygous for said two or more polymorphisms.
 18. The method of claim15, wherein said human is homozygous for said two or more polymorphisms.19. The method of claim 15, wherein said method comprises detecting thepresence of three or more polymorphisms in SEQ ID NO:1 in said human.20. The method of claim 15, said method comprises determining that thesize of said brain aneurysm is between 2 and 10 mm in diameter andcomprises determining that the location of said brain aneurysm is in ananterior communicating artery or a posterior communicating artery ofsaid human, wherein the presence of said two or more polymorphisms insaid human and the presence of said size and said location indicatesthat said brain aneurysm should be treated.